Background
2 The company was incorporated on 1 February 2010 as an unlisted public company limited by shares. It has 84,160,377 ordinary shares on issue and 93 members.
3 The company has two wholly-owned subsidiaries, neither of which is in external administration. One is Ellume USA LLC (Ellume USA), a Delaware limited liability company which operates solely in the United States of America. The other is Ellume NZ Pty Ltd, incorporated in New Zealand. The New Zealand subsidiary has never traded, has no assets or liabilities and has no financial accounts.
4 The company and Ellume USA were operated as a group.
5 During the COVID-19 epidemic, the company developed a COVID-19 home test kit which was approved by the US Food and Drug Administration. That led to a very substantial order on Ellume USA from the US Department of Defence and the commitment of very substantial capital to the manufacture of the test kits. The company obtained substantial funding via unsecured noteholders, as well as funding from Ellume USA. Unfortunately, the kits proved to be defective which led to a recall and substantial losses for the group.
6 On 31 August 2022, the deed administrators were appointed jointly and severally as voluntary administrators of the company in accordance with a resolution of its directors pursuant to s 436A of the Act.
7 On 8 September 2022, the administrators caused the company to enter into a funding agreement to provide the company with short-term liquidity to allow it to continue to trade while the administrators undertook a sale/recapitalisation campaign. On 13 September 2022, orders were made approving the administrators' conclusion of the funding agreement.
8 The sale/recapitalisation campaign involved contacting a large number of potentially interested parties and inviting expressions of interest. Although there was significant interest, and following a process of receipt of non-binding indicative offers and then an invitation for binding offers, only one final binding offer was received. That was from Hough. A joint non-binding offer was received by two other shortlisted bidders.
9 The administrators assessed each proposal and, on 6 December 2022, selected Hough to proceed to the final phase of the sale/recapitalisation process. To the administrators, a critical point of difference between the proposals was that the Hough proposal was binding and was able to address the company's immediate funding needs, which the other offer lacked.
10 The administrators and Hough negotiated the terms of the transaction. This led to the binding agreement (subject to a number of conditions precedent, including the order under s 444GA of the Act sought in this application) for the share transfer through a deed of company arrangement and a subsequent creditors' trust to provide for the payment of creditors.
11 The Hough transaction envisages a proposed deed of company arrangement (DOCA). That involves:
(1) Hough acquiring all of the issued shares in the company;
(2) the formation of a creditors' trust (of which the deed administrators would become trustees) to meet the claims of creditors in a particular priority;
(3) Hough making a contribution of US$38 million to the creditors' trust, inclusive of the interim funding of US$5 million;
(4) all employees of the company remaining employed by the company on the DOCA becoming effective and any employees whose employment does not continue having their entitlements paid out in full; and
(5) members of the company receiving no payment from the creditors' trust and no other payment in return for the transfer of their shares to Hough.
12 On 12 December 2022, the administrators issued their report to the creditors of the company pursuant to s 75-225 of the Insolvency Practice Rules (Corporations) 2016 (Cth) and convened the second meeting of creditors.
13 That meeting was held on 20 December 2022. The administrators recommended that the creditors vote in favour of the DOCA proposal on the basis that it would not be in the creditors' interests for the company to be would up as the DOCA would likely provide a greater return than a winding up of the company and carried less uncertainty. The administrators remain of the view that completion of the DOCA is in the best interests of the creditors of the company.
14 The resolution that the company execute the DOCA passed in both number (98.60%) and value (99.23%).
15 The DOCA was executed by the administrators, Hough and the company on 22 December 2022. As mentioned, it is a condition precedent to completion that the deed administrators apply for and obtain the leave that is presently sought.
16 The completion of the restructure of the company involves:
(1) a transfer of the shares in the company to Hough pursuant to a s 444GA order;
(2) execution of a trust deed to create the creditors' trust fund; and
(3) payment of the contribution of US$38 million (less the interim funding) by Hough.
17 Because the company is an unlisted company with more than 50 members, it is also subject to the prohibitions in s 606 of the Act, which has required the deed administrators to seek relief from ASIC from the takeover provisions in Ch 6 of the Act pursuant to the power conferred on ASIC by s 655A(1)(a).
18 On 27 January 2023, the deed administrators submitted an application to ASIC seeking relief from s 606 to facilitate the proposed share transfer. On 16 February 2023, ASIC indicated that it was still considering the application and requested copies of the papers in the application to court for approval and confirmation as to whether any interested persons had indicated that they may lodge a notice of appearance to oppose the application. I understand that that request was complied with.
19 By letter dated 21 February 2023, ASIC has indicated a decision in principle that it will grant the relief sought in the application to it. ASIC has said that it proposes to execute the formal instrument of relief if and only if the Court grants leave to the deed administrators under s 444GA of the Act to transfer all of the existing shares to Hough pursuant to the DOCA. ASIC has not raised any reason why the Court might not grant the s 444GA relief and has not indicated any opposition to the granting of that relief.